Competition of carrier bioresorption and drug release kinetics of vancomycin-loaded silicate macroporous microspheres to determine cell biocompatibility

This study demonstrates that the biocompatibility of vancomycin-loaded magnesium-calcium silicate microspheres (bredigite, akermanite, and diopside) is primarily determined by the carrier's bioresorption kinetics rather than the drug release rate, with diopside microspheres exhibiting the highest cell viability.

The Gist

Imagine your body is a bustling city, and sometimes, due to an injury or surgery, a neighborhood (a bone) gets damaged, leaving a big empty lot. To fix this, doctors need to fill that hole with something that acts like a temporary scaffold, helping the city rebuild itself.

This research paper is about testing three different types of "construction scaffolds" made from special glass-like minerals (silicates) to see which one is the best for helping bone cells grow, especially when those scaffolds are also carrying a powerful antibiotic (Vancomycin) to fight infection.

Here is the story of the experiment, broken down simply:

1. The Three Construction Crews

The scientists created three different types of microscopic, sponge-like balls (microspheres). Think of them as three different brands of biodegradable sponges designed to dissolve slowly as new bone grows. They are made of calcium and magnesium silicates, but they have slightly different chemical recipes:

• Bredigite: The "fast-dissolver."
• Akermanite: The "medium-dissolver."
• Diopside: The "slow-dissolver."

They loaded all three types of sponges with the same amount of Vancomycin, a strong antibiotic used to stop bone infections (like osteomyelitis).

2. The Test: A Garden Party for Cells

To see which sponge was the safest and most helpful, the scientists held a "garden party" for human bone stem cells (the workers that build new bone).

• They placed the cells on top of the three different antibiotic-loaded sponges.
• They watched how happy and healthy the cells were after 1, 3, and 7 days.
• They compared this to a control group (cells in a plain nutrient soup with no sponges).

3. The Surprise Result: It's Not About the Medicine

You might think the sponge that released the most medicine would be the best at killing bacteria, or perhaps the one that released the least would be the safest. But the results were surprising.

• Day 1: All three sponges were fine. The cells didn't mind the initial "burst" of antibiotic coming out.
• Days 3 & 7: A clear winner emerged.
  • Diopside (Slow-dissolver): The cells loved this one. They grew the best, even better than the control group!
  • Akermanite (Medium-dissolver): The cells were okay, doing just as well as the control group.
  • Bredigite (Fast-dissolver): The cells struggled here. They didn't grow as well as the others.

4. The "Why": The Lemonade Analogy

Why did the slow-dissolving sponge win? The scientists realized that the drug (antibiotic) wasn't the main problem; the sponge itself was.

Imagine the sponges are like lemonade dispensers:

• The Drug (Vancomycin): This is the sugar in the lemonade. The study found that even though the "fast-dissolver" (Bredigite) dumped a huge amount of sugar (drug) out immediately, the cells didn't get a "sugar shock." The drug was safe enough that it didn't hurt the cells, even in a big burst.
• The Sponge (Carrier): This is the water and the lemon juice. As the sponge dissolves, it releases minerals (ions) into the water.
  • The Fast-dissolver (Bredigite) dissolved so quickly that it dumped too many minerals into the water too fast. This changed the "flavor" (pH level) of the environment, making it too alkaline (like adding too much baking soda). The cells got confused and couldn't thrive.
  • The Slow-dissolver (Diopside) released its minerals gently and steadily. It kept the environment just right, like a perfectly balanced lemonade, allowing the cells to flourish.

The Big Takeaway

The main lesson of this paper is a competition between two things:

1. How fast the drug comes out.
2. How fast the sponge dissolves.

The study concluded that how fast the sponge dissolves is much more important for the cells' health than how fast the drug comes out. Even though the drug was the same for all three, the one that dissolved too fast made the environment toxic for the cells.

In short: If you are building a scaffold for bone repair, you want a material that dissolves slowly and gently (like Diopside) rather than one that falls apart too quickly, even if you are loading it with life-saving medicine.

Technical Summary

1. Problem Statement

Bone defects, particularly those resulting from trauma or surgery, carry a significant risk of osteomyelitis (bone infection). While antibiotic-loaded bone cements (e.g., PMMA) are commonly used, they suffer from non-biodegradability, necessitating secondary removal surgeries. Bioresorbable ceramics offer a solution, but their application in drug delivery systems requires a precise understanding of how the carrier's degradation competes with drug release kinetics to affect cell viability.

The specific challenge addressed in this study is determining which factor—carrier bioresorption (ion release) or antibiotic release kinetics—plays the dominant role in the cytocompatibility of magnesium-calcium silicate microspheres loaded with vancomycin. The authors compared three specific silicate phases with varying chemical compositions and structural stabilities:

• Bredigite ($Ca_7MgSi_4O_{16}$)
• Akermanite ($Ca_2MgSi_2O_7$)
• Diopside ($CaMgSi_2O_6$)

2. Methodology

Material Synthesis:

• Sol-Gel Process: Calcium nitrate, magnesium nitrate, and tetraethyl orthosilicate (TEOS) were used as precursors to synthesize powders with stoichiometric ratios for bredigite, akermanite, and diopside.
• Calcination: Powders were dried and calcined at 1300°C for 3 hours to form crystalline phases.
• Microsphere Fabrication: A droplet extrusion technique was employed. Silicate powders were mixed with spherical carbon porogens (mass ratio 2:3) and sodium alginate. The suspension was extruded into a calcium chloride solution to cross-link the alginate, forming microspheres.
• Sintering: The microspheres were sintered at 1000°C for 2 hours. The burning of carbon porogens created interconnected macropores.
• Drug Loading: The fabricated microspheres were impregnated with vancomycin hydrochloride via immersion in a 0.05% solution (microsphere/drug mass ratio of 120:1).

Characterization and Testing:

• Structural Analysis: X-ray Diffraction (XRD) was used to confirm phase purity and calculate crystallite sizes. Scanning Electron Microscopy (SEM) analyzed pore structure and interconnectivity.
• Cytocompatibility Assessment: Human bone marrow mesenchymal stem cells (hBM-MSCs) were seeded onto the vancomycin-loaded microspheres. Cell viability and proliferation were evaluated using the MTT assay at 1, 3, and 7 days.
• Statistical Analysis: Variance analysis (ANOVA) was performed with a significance level of $p < 0.05$.

3. Key Contributions

• Comparative Analysis of Silicate Phases: The study provides a direct comparison of three distinct Mg-Ca silicate phases (bredigite, akermanite, diopside) within the same macroporous microsphere architecture, isolating the effect of chemical composition on biological performance.
• Decoupling Kinetics: The research successfully distinguishes between the effects of initial drug burst release and long-term carrier degradation on cell health.
• Mechanistic Insight: It establishes a hierarchy of biocompatibility based on the silicon content and structural stability of the silicates, linking chemical composition directly to physiological pH shifts and ion release.

4. Results

Structural Characterization:

• Phase Purity: XRD confirmed the successful formation of monophase structures for all three ceramics.
• Crystallite Size: Estimated via the Scherrer equation, the sizes were ~57 nm (bredigite), ~35 nm (akermanite), and ~48 nm (diopside). These variations were attributed to differences in melting points and homologous temperatures during calcination.
• Morphology: SEM revealed uniformly distributed, interconnected macropores ranging from 80 to 2000 nm, essential for nutrient transport and drug adsorption.

Drug Release vs. Cytocompatibility:

• Initial Burst (Day 1): All three microspheres exhibited a significant burst release of vancomycin within the first 24 hours (85% for bredigite, 72% for akermanite, 60% for diopside). Despite these high and unequal release rates, no statistically significant difference in cell viability was observed between the samples and the control group on Day 1. This indicates that the initial burst release of vancomycin, even at high levels, was not cytotoxic.
• Long-term Culture (Days 3 and 7): As the culture period extended, distinct differences in cell viability emerged. The ranking of biocompatibility was:
  $$\text{Diopside} > \text{Akermanite} > \text{Bredigite}$$
  • Diopside: Exhibited the highest cell viability (higher than the control).
  • Akermanite: Showed intermediate viability (equivalent to control).
  • Bredigite: Showed the lowest viability (lower than the control).

Mechanism of Action:

• The divergence in biocompatibility after Day 1 correlated with the bioresorption kinetics of the carriers rather than drug release.
• Diopside has the highest silicon content and structural stability, leading to slower ion release and minimal pH disturbance.
• Bredigite has the lowest silicon content, resulting in rapid bioresorption, excessive ion release, and a shift in physiological pH toward alkalosis, which deteriorated cell biocompatibility.
• The contribution of carrier bioresorption to cytocompatibility was found to prevail over drug release kinetics in the long term.

5. Significance

This study is significant for the development of next-generation bone void fillers and drug delivery systems in orthopedics and dentistry. It demonstrates that:

1. Material Selection is Critical: The choice of silicate phase is more critical than the drug loading profile for long-term cell survival. High bioresorbability (as seen in bredigite) can be detrimental if it causes rapid pH shifts.
2. Safety of Antibiotic Bursts: The initial burst release of vancomycin, often a concern for "drug shock," was shown to be safe for hBM-MSCs, validating the use of high-loading strategies to prevent early-stage bacterial biofilm formation.
3. Design Guidelines: For optimal clinical outcomes, drug delivery carriers should be engineered with sufficient structural stability (e.g., diopside) to ensure a controlled release of ions that maintains physiological pH, thereby supporting tissue regeneration while delivering antibiotics.

In conclusion, the authors successfully demonstrated that carrier bioresorption kinetics are the primary determinant of cell biocompatibility in vancomycin-loaded silicate microspheres, outweighing the influence of drug release rates over extended periods.